Johns Hopkins University and DuPont have signed license and collaboration agreements allowing DuPont to commercialize a garment with innovative features from Johns Hopkins to help protect people on the front lines of the Ebola crisis and future deadly infectious disease outbreaks. DuPont intends to have the first of these garments available in the marketplace during the first half of 2016.
Matt Petney, who served as a project manager at Johns Hopkins during development of the improved Ebola protection suit, helps Allie Sibole, a recent graduate, to don the prototype garment. Photo courtesy of Will Kirk/JHU
Johns Hopkins University and DuPont have signed license and collaboration agreements allowing DuPont to commercialize a garment with innovative features from Johns Hopkins to help protect people on the front lines of the Ebola crisis and future deadly infectious disease outbreaks. DuPont intends to have the first of these garments available in the marketplace during the first half of 2016.
The collaboration between the major research university and the international science and engineering company began in response to the humanitarian need identified by the U.S. Agency for International Development (USAID) during the recent Ebola outbreak in West Africa. In this region, the Ebola virus has infected more than 28,000 patients and resulted in more than 11,000 deaths. Harsh climates and ill-equipped health systems have led to tough working conditions that made it particularly difficult to keep the infections at bay. As the disease spread, many nurses, doctors and others were fatally infected by the patients they were treating. The World Health Organization has confirmed more than 800 Ebola cases among health workers in Guinea, Liberia and Sierra Leone, leading to more than 500 related deaths.
As this grim toll came to light, public health experts, scientists and biomedical engineers in the public and private sectors were called on to help. In December, the USAID selected the new Johns Hopkins prototype protective garment, made of a DuPont advanced material, as one of the first five projects to receive funding to address the health-care challenge posed by Ebola.
The prototype garment was developed by the Johns Hopkins Center for Bioengineering Innovation and Design (CBID), with input from global health partner Jhpiego, a Johns Hopkins affiliate. Incorporating some elements from the Johns Hopkins prototype, the garment design from DuPont will feature a rear zipper and a “cocoon-style” removal, or doffing, process that requires far fewer steps to reduce risk. The DuPont garment may include an integrated hood with a large clear visor.
The collaboration with DuPont, a global leader in personal protective apparel, will expedite wide market access for the garment. For more than 40 years, the company has been providing such apparel to help protect the safety of industrial and healthcare workers. Under the agreements, Johns Hopkins will assist DuPont in evaluating prototype garments produced by DuPont and will aid in the preparation of information for users. DuPont will be responsible for all aspects of commercialization. Further terms of the agreements were not disclosed.
“This unique collaboration,” says Youseph Yazdi, executive director of CBID, “brings together the biomedical ingenuity of Johns Hopkins, the global health-care experience of Jhpiego and the strategic industrial innovations of DuPont to help save lives worldwide. Although this project was triggered by the recent Ebola outbreak, we believe the improved protective suit’s design will be impactful in future infectious disease outbreaks as well.”
Marc Doyle, senior vice president of DuPont Safety & Protection, adds, “Our participation in the USAID Grand Challenge and subsequent collaboration with Johns Hopkins and Jhpiego is an example of how DuPont engages with partners to address a global challenge. We look forward to the next step of making this protective apparel solution available where it is needed for both emergency response and preparedness.”
Jhpiego will field-test the DuPont prototype garment in Liberia, one of the three African countries hit hardest by the recent Ebola outbreak. Liberia is a nation where Jhpiego has deep roots and experience in health systems strengthening and training of health workers.
Leslie Mancuso, president and CEO of Jhpiego, says the new garment will help ensure that frontline health workers can respond safely and with confidence to any new infectious disease outbreak. “Hundreds of nurses, midwives and physicians selflessly responded to the Ebola outbreak and lost their lives trying to save others. The response of Johns Hopkins, Jhpiego and DuPont to the humanitarian challenge offers a model of the ingenuity and dedication of the public and private sector to improve global health.”
Source: Johns Hopkins University
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.